ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.2238G>C (p.Trp746Cys) (rs1800312)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000508344 SCV000603775 pathogenic not specified 2016-11-16 criteria provided, single submitter clinical testing
Counsyl RCV000283919 SCV000678008 pathogenic Glycogen storage disease, type II 2017-06-16 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000254988 SCV000333710 pathogenic not provided 2018-07-20 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000283919 SCV000893477 pathogenic Glycogen storage disease, type II 2018-10-31 criteria provided, single submitter clinical testing
GeneDx RCV000254988 SCV000321685 pathogenic not provided 2018-09-28 criteria provided, single submitter clinical testing The W746C variant in the GAA gene has been reported previously in both the compound heterozygous and homozygous state in individuals with juvenile/late-onset glycogen storage disease II (GSDII) (Wan et al., 2008; Lui et al., 2014). Functional studies are consistent with W746C being a 'mild' GAA variant (Nino et al., 2013, Kroos et al., 2008, Wan et al., 2008). Although not observed as homozygous, the W746C variant is observed in 72/126398 (0.057%) alleles from individuals of non-Finnish European background and 84/276822 (0.03%) total alleles in large population cohorts (Lek et al., 2016). This variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. In addition, a different missense variant at the same position (W746R) has been reported in association with GSDII (Nino et al., 2013). We interpret W746C as a pathogenic variant.
Illumina Clinical Services Laboratory,Illumina RCV000283919 SCV000407295 pathogenic Glycogen storage disease, type II 2017-04-27 criteria provided, single submitter clinical testing The GAA c.2238G>C (p.Trp746Cys) variant has been reported in at least six studies in which it is found in a total of 31 individuals with glycogen storage disease, type II, including three in a homozygous state, 27 in a compound heterozygous state, and one in a heterozygous state in whom a second variant was not identified (Huie et al. 1994; Wan et al. 2008; Yang et al. 2011; Liu et al. 2014; Liong et al. 2014; Zhang et al. 2016). Ten of the compound heterozygous individuals were found to carry a second GAA variant in cis with the p.Trp746Cys variant (Huie et al. 1994; Yang et al. 2011). However, functional studies in cell lines demonstrated that expression of the p.Trp746Cys variant alone resulted in enzymatic activity that was 10-29% of wild type GAA activity (Huie et al. 1994; Huie et al. 1998; Yang et al. 2011; Nino et al. 2013). The p.Trp746Cys variant was absent from 100 controls and is reported at a frequency of 0.00048 in the European (non-Finnish) population of the Exome Aggregation Consortium. Based on the evidence, the p.Trp746Cys variant is classified as pathogenic for glycogen storage disease, type II. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Integrated Genetics/Laboratory Corporation of America RCV000283919 SCV000695651 pathogenic Glycogen storage disease, type II 2016-03-03 criteria provided, single submitter clinical testing
Invitae RCV000283919 SCV000626554 pathogenic Glycogen storage disease, type II 2019-01-06 criteria provided, single submitter clinical testing This sequence change replaces tryptophan with cysteine at codon 746 of the GAA protein (p.Trp746Cys). The tryptophan residue is highly conserved and there is a large physicochemical difference between tryptophan and cysteine. This variant is present in population databases (rs1800312, ExAC 0.05%). This variant has been reported in the literature in multiple individuals affected with Pompe disease both in the heterozygous and in the homozygous state (PMID: 18458862, 21757382, 21232767, 23430493, 25526786, 27099502) and it is considered a mild/moderate late-onset Pompe disease variant (PMID: 21232767, 25526786, 27099502, 25093132). ClinVar contains an entry for this variant (Variation ID: 265160). Experimental studies have shown that this missense change causes a moderate reduction on GAA enzyme activity in vitro (PMID: 21757382, 9535769, 7981676). For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000825562 SCV000966888 pathogenic Glycogen storage disease 2018-08-08 criteria provided, single submitter clinical testing The p.Trp746Cys variant in GAA has been reported in at least 2 homozygous and 24 compound heterozygous Asian individuals with juvenile- or adult-onset glycogen storage disease type II (GSDII) also known as Pompe disease (Wan 2008, Chien 20 11, Yang 2011, Liu 2014, Liong 2014, Zhang 2016, Lee 2017, Park 2017), and segre gated with GSDII in 3 affected relatives from 2 families (Yang 2011, Liu 2014). This variant has been identified in 72/126398 European and 6/18864 East Asian ch romosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitu te.org; dbSNP rs1800312). Although this variant has been seen in the general pop ulation, its frequency is low enough to be consistent with a recessive carrier f requency. Computational prediction tools and conservation analysis suggest that the p.Trp746Cys variant may impact the protein. In vitro functional studies prov ide some evidence that the p.Trp746Cys variant may impact protein function (Huie 1994, Huie 1998, Yang 2011, Nino 2013). In summary, this variant meets criteria to be classified as pathogenic for GSDII in an autosomal recessive manner. ACMG /AMP Criteria applied: PM3_VeryStrong, PS3_Moderate, PP1, PP3, PP4.
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000254988 SCV000800888 pathogenic not provided 2017-01-03 no assertion criteria provided clinical testing
SIB Swiss Institute of Bioinformatics RCV000283919 SCV000803623 likely pathogenic Glycogen storage disease, type II 2018-05-31 criteria provided, single submitter curation This variant is interpreted as a Likely Pathogenic, for Glycogen storage disease 2, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PS3 => Well-established functional studies show a deleterious effect (PMID:18458862).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.